Urogen Pharma (NASDAQ:URGN) Stock Has Consensus Target Price of $53.38 According to Brokerages

Urogen Pharma (NASDAQ:URGN) has been assigned a consensus rating of “Moderate Buy” from the ten analysts that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $53.38.

URGN has been the subject of a number of analyst reports. Oppenheimer set a $60.00 price target on Urogen Pharma in a research report on Thursday, November 5th. HC Wainwright reiterated a “buy” rating and set a $75.00 price objective on shares of Urogen Pharma in a research report on Monday, October 19th. Guggenheim lowered their price objective on Urogen Pharma from $58.00 to $56.00 and set a “buy” rating on the stock in a research note on Thursday, November 5th. Jefferies Financial Group restated a “buy” rating and issued a $56.00 target price on shares of Urogen Pharma in a report on Thursday, September 10th. Finally, TD Cowen raised their target price on Urogen Pharma from $50.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th.

Urogen Pharma Stock Up 1.1%

Shares of NASDAQ:URGN opened at $26.39 on Friday. The business’s 50-day moving average is $37.38 and its 200 day moving average is $31.65. Urogen Pharma has a 1 year low of $16.50 and a 1 year high of $50.81.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Wednesday, November 4th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.14). The firm had revenue of $89.00 million during the quarter, compared to analyst estimates of $89.92 million. On average, equities research analysts predict that Urogen Pharma will post -0.36 EPS for the current year.

Insider Activity

In related news, CFO Chris Degnan sold 2,202 shares of Urogen Pharma stock in a transaction on Thursday, October 8th. The stock was sold at an average price of $36.69, for a total value of $80,791.38. Following the completion of the transaction, the chief financial officer directly owned 4,561 shares in the company, valued at approximately $167,343.09. This trade represents a 32.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Mark Schoenberg sold 871 shares of Urogen Pharma stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $42.92, for a total value of $37,383.32. Following the completion of the transaction, the insider owned 59,882 shares of the company’s stock, valued at $2,570,135.44. The trade was a 1.43% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 65,269 shares of company stock valued at $3,037,646. Company insiders own 4.80% of the company’s stock.

Institutional Trading of Urogen Pharma

Several institutional investors have recently modified their holdings of URGN. BlackRock Inc. acquired a new position in Urogen Pharma in the second quarter valued at $117,814,000. Jefferies Financial Group Inc. acquired a new stake in Urogen Pharma during the 2nd quarter worth approximately $80,947,000. Bank of America Corp DE acquired a new stake in Urogen Pharma during the 2nd quarter worth approximately $17,506,000. Rice Hall James & Associates LLC purchased a new position in shares of Urogen Pharma in the 2nd quarter valued at approximately $11,064,000. Finally, ADAR1 Capital Management LLC purchased a new position in shares of Urogen Pharma in the 2nd quarter valued at approximately $9,288,000. Hedge funds and other institutional investors own 91.29% of the company’s stock.

Urogen Pharma Company Profile

UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing treatments for cancers of the urinary tract. Its work centers on therapies delivered directly to the urinary system, including treatments for certain forms of urothelial cancer. The company’s products include Jelmyto, a mitomycin-based treatment delivered to the upper urinary tract for adults with low-grade upper tract urothelial cancer, and Zusduri, a mitomycin-based treatment for adults with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer.